Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

IMPACT Trialists Group, Ian E Smith, Mitch Dowsett, Stephen R Ebbs, J Michael Dixon, Anthony Skene, J-U Blohmer, Susan E Ashley, Stephen Francis, Irene Boeddinghaus, Geraldine Walsh

Research output: Contribution to journalArticlepeer-review

Abstract

The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of neoadjuvant tamoxifen compared with anastrozole and with the combination of tamoxifen and anastrozole before surgery in postmenopausal women with estrogen receptor (ER) -positive, invasive, nonmetastatic breast cancer might predict for outcome in the Arimidex, Tamoxifen Alone or in Combination (ATAC) adjuvant therapy trial.
Original languageEnglish
Pages (from-to)5108-16
Number of pages9
JournalJournal of Clinical Oncology
Volume23
Issue number22
DOIs
Publication statusPublished - 1 Aug 2005

Keywords

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Double-Blind Method
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy
  • Nitriles
  • Odds Ratio
  • Placebos
  • Postmenopause
  • Tamoxifen
  • Treatment Outcome
  • Triazoles

Fingerprint Dive into the research topics of 'Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial'. Together they form a unique fingerprint.

Cite this